The beginning of the year saw a spurt of IPO activity, but it's since cooled off. A declining stock market and pullback from ...

Bluebird Bio reviews an unsolicited $4.50 per share bid from Ayrmid after agreeing to a $3.00 per share buyout with Carlyle and SK Capital.

Ayrmid has offered to buy bluebird for an upfront cash payment of $4.50 a share and a one-time contingent value right of $6.84 a share, payable upon achievement of a net sales milestone, said ...

Key players in the foreign exchange market are concerned about the potential of a "liquidity mirage," as they fear a proliferation of trading platforms and the widespread use of automation are ...

Drench in the knowledge with exclusive insights, ePaper & smart market tools with ETPrime.